Comorbidities role on death in diabetic patients with COVID-19 

Purpose: According to the possible role of other comorbidities in increase the risk of mortality in diabetes patient, recent study was designed to manage complications and mortality rate in this group of patients.Methods: In this cross-sectional study (25 February to 10 July 2020) total of 458 diabetic patients were enrolled based on their characteristics, symptoms and signs, and presence of underlying diseases. Multiple logistic regression and χ2 test analysis used to check the effectiveness of comorbidities on the mortality outcome among diabetic patients.Results: Of 458 diabetic patients, 306 (67%) were with underlying diseases (200 (65.4%) hypertension, 103 (33.7%) cardiovascular diseases and 29 (9.5%) kidney diseases). The rate of fatality was significantly high in patients with chronic kidney and liver diseases. The odds of mortality outcome increase 3.1 fold for patients over 55 years as compared to under 55 years (P =0.011), and the odds of mortality outcome was more than 5.1 folds for those who had chronic kidney disease (P <0.001).Conclusions: The presentation of SARS-CoV-2 in older diabetic patients with comorbidities (chronic kidney and liver diseases) is more severe in risk of mortality.

[1]  Zumin Shi,et al.  Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis , 2020, Diabetes Research and Clinical Practice.

[2]  Shima Shahyad,et al.  Psychological impacts of Covid-19 outbreak on mental health status of society individuals: A narrative review , 2020 .

[3]  Ritesh Gupta,et al.  Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[4]  R. Holt,et al.  COVID‐19 and diabetes , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[5]  Heng Fan,et al.  Diabetes is a risk factor for the progression and prognosis of COVID‐19 , 2020, Diabetes/metabolism research and reviews.

[6]  A. Akbari,et al.  Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis , 2020, Archives of academic emergency medicine.

[7]  Edward Livingston,et al.  Coronavirus Disease 2019 (COVID-19) in Italy. , 2020, JAMA.

[8]  C. Whittaker,et al.  Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand , 2020 .

[9]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[10]  Z. Bloomgarden.  Diabetes and COVID‐19 , 2020, Journal of diabetes.

[11]  W. Tu,et al.  Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit , 2020, Intensive Care Medicine.

[12]  M. Baig,et al.  Association of Dyslipidemia and Comorbidities with Risk Factors Among Diabetic Patients: A Retrospective Analysis , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[13]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[14]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[15]  De-Min Han,et al.  Gender Differences in Patients With COVID-19: Focus on Severity and Mortality , 2020, Frontiers in Public Health.

[16]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[17]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[18]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[19]  M. Moghadami,et al.  Characteristics of deceased patients with CoVID-19 after the first peak of the epidemic in Fars province, Iran , 2020, Infection ecology & epidemiology.

[20]  C. Midgley,et al.  Diabetes Mellitus, Hypertension, and Death among 32 Patients with MERS-CoV Infection, Saudi Arabia , 2020, Emerging infectious diseases.

[21]  Siddhartha Das,et al.  A possible alternate pathway for intravascular thrombosis - Investigation of the circumstantial evidence by microfluidics , 2017 .

[22]  Jihad Ghandour,et al.  Middle East Respiratory Syndrome Coronavirus: A Case-Control Study of Hospitalized Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  S. Knapp,et al.  Diabetes and Infection: Is There a Link? - A Mini-Review , 2012, Gerontology.

[24]  R. Allard,et al.  Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection , 2010, Diabetes Care.

[25]  J. Chan,et al.  Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[26]  F. Schellevis,et al.  Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Hux,et al.  Quantifying the risk of infectious diseases for people with diabetes. , 2003, Diabetes care.

[28]  D. Simonson.  Etiology and Prevalence of Hypertension in Diabetic Patients , 1988, Diabetes Care.